Correlation Between Ultragenyx and Alnylam Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Ultragenyx and Alnylam Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Ultragenyx and Alnylam Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Ultragenyx and Alnylam Pharmaceuticals, you can compare the effects of market volatilities on Ultragenyx and Alnylam Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Ultragenyx with a short position of Alnylam Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Ultragenyx and Alnylam Pharmaceuticals.

Diversification Opportunities for Ultragenyx and Alnylam Pharmaceuticals

0.44

Correlation Coefficient

Ultragenyx  Alnylam Pharmaceuticals

Very weak diversification

The 3 months correlation between Ultragenyx and Alnylam is 0.44. Overlapping area represents the amount of risk that can be diversified away by holding Ultragenyx and Alnylam Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Alnylam Pharmaceuticals and Ultragenyx is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Ultragenyx are associated (or correlated) with Alnylam Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Alnylam Pharmaceuticals has no effect on the direction of Ultragenyx i.e., Ultragenyx and Alnylam Pharmaceuticals go up and down completely randomly.

Pair Corralation between Ultragenyx and Alnylam Pharmaceuticals

Given the investment horizon of 90 days Ultragenyx is expected to under-perform the Alnylam Pharmaceuticals. In addition to that, Ultragenyx is 1.79 times more volatile than Alnylam Pharmaceuticals. It trades about -0.12 of its total potential returns per unit of risk. Alnylam Pharmaceuticals is currently generating about -0.07 per unit of volatility. If you would invest  15,866  in Alnylam Pharmaceuticals on February 26, 2024 and sell it today you would lose (1,090) from holding Alnylam Pharmaceuticals or give up 6.87% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Ultragenyx  vs.  Alnylam Pharmaceuticals

Ultragenyx

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Ultragenyx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in June 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Alnylam Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Alnylam Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Alnylam Pharmaceuticals is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Ultragenyx and Alnylam Pharmaceuticals

The main advantage of trading using opposite Ultragenyx and Alnylam Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Ultragenyx position performs unexpectedly, Alnylam Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alnylam Pharmaceuticals will offset losses from the drop in Alnylam Pharmaceuticals' long position.

The idea behind Ultragenyx and Alnylam Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.